The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis

Acta Psychiatrica Scandinavica

Volumn 132, Issue 2, 2015, Pages 144-157

  Stubbs, B ^a   Vancampfort, D ^b,c   De Hert, M ^b,c   Mitchell, A J ^d  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

diabetes; glucose abnormality; metabolic syndrome; psychosis; schizophrenia; T2DM mellitus

Indexed keywords

COMPARATIVE STUDY; CONTROL GROUP; DIABETES MELLITUS; HUMAN; LIFESTYLE; META ANALYSIS; METABOLISM; PREDICTIVE VALUE; PREVALENCE; PSYCHOLOGY; RISK FACTOR; SCHIZOPHRENIA;

CONTROL GROUPS; DIABETES MELLITUS; HUMANS; LIFE STYLE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 85027945486     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12439     Document Type: Review

References (57)

1. Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007;64:242–249.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123–1131.
3. Reininghaus U, Dutta R, Dazzan P et al. Mortality in Schizophrenia and Other Psychoses: a 10-Year Follow-up of the ӔSOP First-Episode Cohort. Schizophr Bull 2014;41:664–673.
4. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013;346:f2539.
5. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M. Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. Schizophr Bull 2013;39:306–318.
6. Vancampfort D, Wampers M, Mitchell AJ et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240–250.
7. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222.
8. Ribe AR, Laursen TM, Sandbaek A, Charles M, Nordentoft M, Vestergaard M. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med 2014;44:3097–3107.
9. American Diabetes Association. Screening for type 2 DM. Diabetes Care 2003;26(suppl 1):S21–S24.
10. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS ONE 2009;6:1–6.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders – DSM-IV-TR. 4th ed. New York: American Psychiatric Association; 2000.
13. World Health Organisation. The ICD-10 Classification of Mental and Behavioural Disorders – Diagnostic Criteria for Research. 1993.
14. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. ISBN 92 4 159493 4; 2006.
15. Wells G, Shea B, O'Connell D, Peterson JEA. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 01/12/2013]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
16. Dersimonian R, Laird N. Meta-analysis in clinical trials. Clin Trials 1986;7:177–188.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
18. Egger M. DAVEY SMITH G, SCHNEIDER M, MINDER C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
19. Mäkikyrö T, Karvonen JT, Hakko H et al. Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort. Public Health 1998;112:221–228.
20. Dixon L, Weiden P, Delahanty J et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903–912.
21. Dickerson FB, Pater A, Origoni AE. Health behaviors and health status of older women with schizophrenia. Psychiatr Serv 2002;53:882–884.
22. Curkendall SM, Mo J, Glasser DB. ROSE STANG M, JONES JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65:715–720.
23. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19–27.
24. Sokal J, Messias E, Dickerson FB et al. Comorbidity of Medical Illnesses Among Adults With Serious Mental Illness Who Are Receiving Community Psychiatric Services. J Nerv Ment Dis 2004;192:421–427.
25. Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45–53.
26. Hung C-F, Wu C-K, Lin P-Y. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:523–527.
27. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006;68:684–691.
28. Osborn DPJ, Nazareth I, King MB. Risk for coronary heart disease in people with severe mental illness: cross-sectional comparative study in primary care. Br J Psychiatry 2006;188:271–277.
29. Chien IC, Hsu JH, Lin CH, Bih SH, Chou YJ, Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 2009;111:17–22.
30. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 2009;70:997–1000.
31. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010;117:75–82.
32. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull 2012;38:280–284.
33. Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res 2010;119:145–152.
34. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. Eur Psychiatry 2011;26:327–332.
35. Mai Q, Holman CDAJ, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med 2011;9:118.
36. Nuevo R, Chatterji S, Fraguas D et al. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry 2011;72:1592–1599.
37. Phutane VH, Tek C, Chwastiak L et al. Cardiovascular risk in a first-episode psychosis sample: a ‘critical period’ for prevention? Schizoph Res. 2011;127:257–261.
38. Subashini R, Deepa M, Padmavati R, Thara R, Mohan V. Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J Postgrad Med 2011;57:272–277.
39. Zhang R, Hao W, Pan M et al. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine. Hum Psychopharmacol 2011;26:392–396.
40. Morden NE, Lai Z, Goodrich DE et al. Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. Gen Hosp Psychiatry 2012;34:368–379.
41. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 2012;27:33–42.
42. Schoepf DHRR. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci 2014;264:3–28.
43. Foley DL, Mackinnon A, Morgan VA et al. Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry 2014;13:176–183.
44. Manu P, Correll CU, Wampers M et al. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol 2013;23:205–211.
45. Wilmot EG, Edwardson CL, Achana FA et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia 2012;55:2895–2905.
46. Soundy A, Wampers M, Probst M et al. Physical activity and sedentary behaviour in outpatients with schizophrenia: a systematic review and meta-analysis… including commentary by Attux C, Leutwyler H, and Strohle A. Int J Ther Rehabil 2013;20:588–596.
47. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost All Antipsychotics Result in Weight Gain: a Meta-Analysis. PLoS ONE 2014;9:1–19.
48. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, de Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125–147.
49. Correll CU, Robinson DG, Schooler NR et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results From the RAISE-ETP Study. JAMA Psychiatry 2014;71:1350–1363.
50. de Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52–77.
51. de Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138–151.
52. de Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology. Eur Psychiatry 2009;24:412–424.
53. van der Heijden MMP, van Dooren FEP, Pop VJM, Pouwer F. Effects of exercise training on quality of life, symptoms of depression, symptoms of anxiety and emotional well-being in type 2 diabetes mellitus: a systematic review. Diabetologia 2013;56:1210–1225.
54. Craig CL, Marshall AL, Sjöström M et al. International Physical Activity Questionnaire: 12-country reliability and validity. including commentary by Bassett DR Jr. Med Sci Sports Exerc 2003;35:1381–1396.
55. Stubbs B, Probst M, Soundy A et al. Physiotherapists can help implement physical activity programmes in clinical practice. Br J Psychiatry 2014;204:164.
56. Qiu S, Cai X, Schumann U, Velders M, Sun Z, Steinacker JM. Impact of Walking on Glycemic Control and Other Cardiovascular Risk Factors in Type 2 Diabetes: a Meta-Analysis. PLoS ONE 2014;9:1–8.
57. Soundy A, Muhamed A, Stubbs B, Probst M, Vancampfort D. The benefits of walking for individuals with schizophrenia spectrum disorders: a systematic review. Int J Ther Rehabil 2014;21(9):410–420.